Breast Cancer

Endocrine Therapy

ER/PR-POSITIVE HER2 NEGATIVE

HER2 POSITIVE

“TRIPLE NEGATIVE” EP/PR-NEGATIVE HER2-NEGATIVE

Pre-Op Therapy

CDK 4/6i + PARPi

Surgical Therapy

Adjuvant Therapy

1st line MBC Therapy

2nd line MBC Therapy

3rd line MBC Therapy

“No Trial Currently Available

1st line MBC Therapy

No Trial Currently Available

2nd line MBC Therapy

1st line MBC Therapy

No Trial Currently Available

3rd line MBC Therapy

“No Trial Currently Available

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

CROSS-DISEASE TRIALS:

IRB# 19200 DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable/Metastatic Breast Cancer

IRB# 19358 Elacestrant Monotherapy vs. SOC for Advanced BC following CDK4/6 Inhibitor Therapy

IRB# 20440 CT7001 Module 2

IRB# 17887 SGN-LIV1A Part E

IRB# 19830 T-DM1 and Palbociclib in Metastatic HER2+ BC

IRB# 198112 T-DM1 and Tucatinib/Placebo in Metastatic HER2+ BC

IRB# 19200 DS-8201a vs. Physician’s Choice for HER2-low Unresectable/Metastatic BC

IRB# 17878 S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

IRB# 17887 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥1 cm

IRB# 18504 Phase 2 Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer